Clinical Trials Logo

Clinical Trial Summary

The goal of the research was to evaluate the performance of items within the Kizazi Kipya (K2) Orphan and Vulnerable Children (OVC) HIV risk screening tool in identifying HIV-positive children, to optimize an HIV screening tool for OVC and children and adolescents in facility settings and to assess the feasibility and acceptability of home-based HIV risk screening and testing.


Clinical Trial Description

Under the ongoing community-based Kizazi Kipya (K2) OVC project, program staff currently administer a 13-item HIV risk screening tool to all K2 program beneficiaries, and refers those who screen positive to facility-based HIV testing. A subset of this 13-item tool is a module of four items that had previously been used as a standalone four-question screening tool in facilities in Zimbabwe.

The primary objectives of this study are as follows.

1. To evaluate the performance of a lay cadre-administered four-item subset of the K2 HIV risk screening tool that matches the Zimbabwe evidence-based tool in predicting the HIV status of vulnerable children/adolescents represented by two populations: (a) K2 OVC beneficiaries and (b) children/adolescents attending health facilities.

2. To identify additional items in the K2 HIV risk screening tool that could be added to the four-question subset to improve the tool's performance.

3. To assess fidelity to the administration of the OVC HIV screening tool items through structured observations of community case workers in the K2 program.

4. To assess the acceptability of OVC HIV risk screening and testing implemented in the community among OVC beneficiaries in the K2 program.

5. To assess the acceptability and feasibility of integrating the OVC HIV screening tool with HIV testing among OVC community case workers in the K2 program. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04517760
Study type Observational
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact
Status Completed
Phase
Start date February 22, 2018
Completion date September 30, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06281834 - Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Phase 1
Completed NCT04206878 - Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
Recruiting NCT05069688 - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Phase 1
Active, not recruiting NCT03024762 - Active Search for Pediatric HIV/AIDS (ASPA) N/A
Recruiting NCT05006170 - Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV Phase 2
Not yet recruiting NCT03980119 - Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya N/A
Completed NCT03824067 - Impact of Point-of-Care EID for HIV-Exposed Infants N/A